Gonorrhoea - Pipeline Insight, 2025
Description
DelveInsight’s, “Gonorrhoea - Pipeline Insight, 2025,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Gonorrhoea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Gonorrhoea: Overview
Gonorrhoea is a sexually transmitted infection (STI), usually passed on through unprotected vaginal, anal or oral sex. It is caused by bacteria called Neisseria gonorrhoeae or gonococcus. Gonorrhoea used to be known as ""the clap"". Typical symptoms of gonorrhoea include a thick green or yellow discharge from the vagina or penis, pain when peeing and, in women, bleeding between periods. Testing for gonorrhea is done by swabbing the infected site (rectum, throat, and cervix) and identifying the bacteria in the laboratory. Gonorrhoea is usually treated with a single antibiotic injection or a single antibiotic tablet.
""Gonorrhoea - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gonorrhoea pipeline landscape is provided which includes the disease overview and Gonorrhoea treatment guidelines. The assessment part of the report embraces, in depth Gonorrhoea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gonorrhoea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Gonorrhoea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gonorrhoea Emerging Drugs
Further product details are provided in the report……..
Gonorrhoea: Therapeutic Assessment
This segment of the report provides insights about the different Gonorrhoea drugs segregated based on following parameters that define the scope of the report, such as:
Gonorrhoea: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Gonorrhoea therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gonorrhoea drugs.
Gonorrhoea Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Gonorrhoea: Overview
Gonorrhoea is a sexually transmitted infection (STI), usually passed on through unprotected vaginal, anal or oral sex. It is caused by bacteria called Neisseria gonorrhoeae or gonococcus. Gonorrhoea used to be known as ""the clap"". Typical symptoms of gonorrhoea include a thick green or yellow discharge from the vagina or penis, pain when peeing and, in women, bleeding between periods. Testing for gonorrhea is done by swabbing the infected site (rectum, throat, and cervix) and identifying the bacteria in the laboratory. Gonorrhoea is usually treated with a single antibiotic injection or a single antibiotic tablet.
""Gonorrhoea - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gonorrhoea pipeline landscape is provided which includes the disease overview and Gonorrhoea treatment guidelines. The assessment part of the report embraces, in depth Gonorrhoea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gonorrhoea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Gonorrhoea R&D. The therapies under development are focused on novel approaches to treat/improve Gonorrhoea.
This segment of the Gonorrhoea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gonorrhoea Emerging Drugs
- Gepotidacin: GlaxoSmithKline
- Zoliflodacin: Entasis Therapeutics
Further product details are provided in the report……..
Gonorrhoea: Therapeutic Assessment
This segment of the report provides insights about the different Gonorrhoea drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Gonorrhoea
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Gonorrhoea: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Gonorrhoea therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gonorrhoea drugs.
Gonorrhoea Report Insights
- Gonorrhoea Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Gonorrhoea drugs?
- How many Gonorrhoea drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gonorrhoea?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gonorrhoea therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Gonorrhoea and their status?
- What are the key designations that have been granted to the emerging drugs?
- Evofem Biosciences
- GlaxoSmithKline
- Entasis Therapeutics
- Alopexx Pharmaceuticals
- Nobelex Biotech
- Summit Therapeutics
- TherapyX
- AchilleS Vaccines
- Recce Pharmaceuticals
- VenatoRx Pharmaceuticals
- EVO 100
- Gepotidacin
- Zoliflodacin
- F 598
- Research programme: Enoyl-ACP reductase inhibitors
- SMT 571
- GneX 12
- Gonorrhoea vaccine
- RECCE 435
- PBP-539
Table of Contents
50 Pages
- Introduction
- Executive Summary
- Gonorrhoea: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Gonorrhoea – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Gonorrhoea companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Gonorrhoea Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- Gepotidacin: GlaxoSmithKline
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- F 598: Alopexx Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical/Discovery Stage Products
- Comparative Analysis
- GneX 12: TherapyX
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Gonorrhoea Key Companies
- Gonorrhoea Key Products
- Gonorrhoea- Unmet Needs
- Gonorrhoea- Market Drivers and Barriers
- Gonorrhoea- Future Perspectives and Conclusion
- Gonorrhoea Analyst Views
- Gonorrhoea Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
